Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines
Executive Summary
Shaw is the former US President of rival Novartis and a rising figure in big pharma. She will take over the role previously held by Ricks, who became CEO Jan. 1. Conterno will assume President USA role.
You may also be interested in...
Musical Chairs: Lilly Leadership Changes Underscore Confidence In Donanemab Accelerated Approval
Oncology leader Anne White will oversee neuroscience and pain, while Bio-Medicines head Ilya Yuffa will take over for retiring Lilly International president; Loxo CEO will oversee entire oncology business.
Shaw Leaves Lilly To Helm Gilead’s Kite
After heading up Lilly Bio-Medicines for two-and-a-half years, Shaw will take over Gilead’s gene therapy subsidiary. At Lilly, she oversaw the approvals of Olumiant and Emgality and helped grow Taltz.
The Outcomes-Based Reimbursement Experiment
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.